BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY4006895 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY4006895\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06657768-796@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:LY4006895: Phase 1 readout est. (NCT06657768)
DESCRIPTION:LY4006895\, phase 1\, Alzheimer's Disease.\nStudy: A Study of L
 Y4006895 in Healthy Participants With Early Symptomatic Alzheimer's Diseas
 e (AD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ly4006895#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06657768
URL:https://assetmemo.bio/drug/ly4006895#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
